Phase 2 N=100 Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
Lateral Epicondylitis
Primary: Elbow Pain Assessments (VAS), Treated Subjects — 76.6; 77.7; 75.9; 72 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=17 Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
Melanoma · Skin Cancer
Primary: Maximum Tolerated Dose (MTD) — 5 mg
N/A N=147 Cormet Post-PMA Study: New Enrollment
Osteoarthritis · Avascular Necrosis · Rheumatoid Arthritis
Primary: The Number of Unilateral Procedures Which Achieved Composite Clinical Success (CCS) at Month 24 — 104 Implants
Phase 2 N=63 Contrast-enhanced Ultrasound of the Kidney
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
N/A N=209 A Study to Evaluate the Safety of Electronic Vapor Products for 2 Years
Healthy Volunteers
Primary: Blood Pressure — 122.4 mmHg
Phase 4 N=500 Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
Coronary Artery Bypass · Antiplatelet Agents
Primary: The Patency of Saphenous Vein Grafts — 76.5; 88.7; 82.8 percentage of patent SV grafts
N/A N=36 A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'
Pancreatic Pseudocyst
Primary: Number of Participants With Clinical Success — 33 participants — p=0.05
Phase 1 N=64 Gardasil Vaccination in Post Stem Cell Transplant Patients
Gardasil Vaccine · Stem Cell Transplant · Immunogenicity
Primary: Percentage of Subjects Who Developed Antibody Response to the Vaccine. — 18; 20; 20 Participants
Phase 1 N=20 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Cancer · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Parts 1 and 2 — 1; 3; 2; 5 Participants
N/A N=20 Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
N/A N=103 Prospective, Randomized Clinical Investigation of Two Different Postoperative Wound Dressings
Hip Surgery Corrective · Knee Injuries
Primary: Composite Variable Ranging From 0 to 7, Combining Complications (Dressing Failure) Related Surgical Wound, Computed as: 3*(Dressing Change) + 2*Blister + (Pain>=30mm) +…
N/A N=131 The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in AUCpp — -287.8; -31.2 min*mmol/L
Phase 2 N=58 Study of the Vascular Effects of Serelaxin
Coronary Artery Disease
Primary: Statistical Analysis of Change From Baseline to Day 3 in Myocardial Perfusion Endpoints Compared With Mid Perfusion Reserve Index Using ANCOVA End Points — -0.244…
Phase 1 N=45 Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers
Reticulocyte Count
Primary: AUC (0-1176 Hours) — 206974.500; 657417.000; 827904.750; 1360020.000 pg*hr/ml
Phase 1 N=57 The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers
Healthy
Primary: AUC(0-72) — 328215.65; 290827.12 pg/ml·h